CN115177780A - 一种抗粘连的可注射止血水凝胶、制备方法及应用 - Google Patents

一种抗粘连的可注射止血水凝胶、制备方法及应用 Download PDF

Info

Publication number
CN115177780A
CN115177780A CN202211112444.5A CN202211112444A CN115177780A CN 115177780 A CN115177780 A CN 115177780A CN 202211112444 A CN202211112444 A CN 202211112444A CN 115177780 A CN115177780 A CN 115177780A
Authority
CN
China
Prior art keywords
component
polymer material
solution
catechol
hydrogel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202211112444.5A
Other languages
English (en)
Other versions
CN115177780B (zh
Inventor
刘明杰
龚熹
魏聪颖
史尉利
赵天艺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beihang University
Peking University Third Hospital
Original Assignee
Beihang University
Peking University Third Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beihang University, Peking University Third Hospital filed Critical Beihang University
Priority to CN202211112444.5A priority Critical patent/CN115177780B/zh
Publication of CN115177780A publication Critical patent/CN115177780A/zh
Application granted granted Critical
Publication of CN115177780B publication Critical patent/CN115177780B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0031Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/046Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/06Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/08Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10Polypeptides; Proteins
    • A61L24/104Gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/042Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/043Proteins; Polypeptides; Degradation products thereof
    • A61L31/045Gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/048Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/06Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/145Hydrogels or hydrocolloids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/00272-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/02Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075Macromolecular gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424Anti-adhesion agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/04Materials for stopping bleeding
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/06Flowable or injectable implant compositions
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2405/00Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
    • C08J2405/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)

Abstract

本发明涉及一种抗粘连的可注射止血水凝胶、制备方法及应用,属于医用水凝胶材料技术领域。本发明的可注射止血水凝胶包括醛基化A组分高分子材料、邻苯二酚化B组分高分子材料和一价无机盐溶液;醛基化A组分高分子材料中的A组分高分子材料带负电,邻苯二酚化B组分高分子材料中的B组分高分子材料带正电;醛基化A组分高分子材料中的A组分高分子材料为带有糖醛酸的多糖类衍生物;邻苯二酚化B组分高分子材料中的B组分高分子材料为壳聚糖、明胶、聚酰亚胺或聚丙烯酸中的任意一种或多种。本发明的可注射止血水凝胶,解决了现有技术中水凝胶可注射性差、操作复杂、止血时间长、安全性低和术后粘连的问题。

Description

一种抗粘连的可注射止血水凝胶、制备方法及应用
技术领域
本发明涉及医用水凝胶材料技术领域,具体涉及一种抗粘连的可注射止血水凝胶、制备方法及应用。
背景技术
随着材料科学的发展,使用水凝胶作为微创手术时使用的止血材料得到广泛的应用,比如利用双层复合水凝胶敷料来用于抗菌止血的制备方法,解决了单一水凝胶不能同时具有高强度、强粘附性与高吸水性能的问题,但可注射性差,只能用于皮肤表层的外部伤口,无法适应微创手术的需要。又如通过光交联多糖-明胶前驱体溶液制备水凝胶材料用于快速止血的制备方法,但上述方法需要光照刺激来使用水凝胶实现伤口止血,操作过程复杂且对于设备有使用要求,影响微创手术的效果。
另外,对于现有技术中的水凝胶,需要进行温度、pH、紫外、小分子或酶等刺激响应来实现溶胶-凝胶转变。但是,温度、pH刺激的方法不利于水凝胶的保存和使用;紫外刺激的方法会对表皮细胞造成二次伤害且使用不便;若引入小分子,可能产生残留等问题;酶响应虽然对细胞无害,但止血时间较长。
近年来,基于可注射水凝胶的操作简单和有效避免缝合并发症的优点,水凝胶粘合剂有望成为替代手术缝合,实现伤口快速止血的候选方案。然而,传统的水凝胶往往具有双面粘合性,由于其不加选择的粘合会产生组织粘连等临床问题,从而严重限制了其在内脏器官和伤口止血修复中的临床应用,特别是腹腔手术中的应用。而术后粘连的形成可能会导致严重的术后并发症,如慢性盆腔疼痛、肠梗阻和不孕症等,往往需要进行二次手术。
发明内容
鉴于上述分析,本发明实施例旨在提供一种抗粘连的可注射止血水凝胶、制备方法及应用,用以解决现有水凝胶可注射性差、操作复杂、止血时间长、安全性低和术后粘连的问题。
本发明提供了一种抗粘连的可注射止血水凝胶,包括醛基化A组分高分子材料、邻苯二酚化B组分高分子材料和一价无机盐溶液;
其中,醛基化A组分高分子材料中的A组分高分子材料带负电,邻苯二酚化B组分高分子材料中的B组分高分子材料带正电;
醛基化A组分高分子材料中的A组分高分子材料为带有糖醛酸的多糖类衍生物;邻苯二酚化B组分高分子材料中的B组分高分子材料为壳聚糖、明胶、聚酰亚胺或聚丙烯酸中的任意一种或多种。
可选地,按质量份数,醛基化A组分高分子材料50-100份、邻苯二酚化B组分高分子材料50-100份和一价无机盐溶液500-1000份。
可选地,一价无机盐溶液为氯化钠或氯化钾溶液。
可选地,多糖类衍生物为透明质酸、果胶、海藻酸钠、硫酸皮肤素、硫酸类肝素或硫酸软骨素中的任意一种或多种。
另一方面,本发明还提供了一种抗粘连的可注射止血水凝胶的制备方法,用于制备前述的水凝胶,包括以下步骤:
制备醛基化A组分高分子材料:获取A组分高分子材料、高碘酸钠溶液、水和乙醇;混合A组分高分子材料和高碘酸钠溶液获得A组分高分子材料溶液;向A组分高分子材料溶液中加入乙醇获得A组分高分子材料反应溶液;将A组分高分子材料反应溶液倒入水中透析,然后冷冻干燥至无质量变化后,获得醛基化A组分高分子材料;
制备邻苯二酚化B组分高分子材料:获取B组分高分子材料、磷酸缓冲液、3,4-二羟基苯乙酸、1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐、水和乙醇;将B组分高分子材料溶于磷酸缓冲液中获得B组分高分子材料溶液;将3,4-二羟基苯乙酸溶于水中获得3,4-二羟基苯乙酸溶液;将1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐溶于水和乙醇中获得1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐溶液;混合3,4-二羟基苯乙酸溶液、1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐溶液和B组分高分子材料溶液获得B组分高分子材料反应溶液;将B组分高分子材料反应溶液倒入水中透析,然后冷冻干燥至无质量变化,获得邻苯二酚化B组分高分子材料;
将醛基化A组分高分子材料溶于水中获得醛基化A组分高分子材料溶液;将邻苯二酚化B组分高分子材料溶于水中获得邻苯二酚化B组分高分子材料溶液;
将醛基化A组分高分子材料溶液和邻苯二酚化B组分高分子材料溶液混合得到复合物;对复合物进行离心处理,将离心后的复合物冷冻干燥后溶于一价无机盐溶液中,得到抗粘连的可注射止血水凝胶。
第三方面,本发明还提供了一种前述的抗粘连的可注射止血水凝胶在制备医疗材料中的应用。
与现有技术相比,本发明可实现如下有益效果:
(1)本发明的水凝胶使用的原料为来源广泛、价格低廉的带相反电荷的天然和/或合成高分子材料组成,具有较高的普适性。
(2)本发明不需温度、pH或者紫外光照等刺激,而是利用盐浓度差的驱动,即:通过高分子材料之间静电相互作用得到复合物;再根据带电高分子材料的盐屏蔽效应,用高浓度盐溶解复合物得到可注射止血水凝胶的粘稠溶液,然后将其注射至出血的创口处。由于可注射止血水凝胶的粘稠溶液和血液的盐浓度不同,可注射止血水凝胶的粘稠溶液中存在大量的小分子盐会快速的扩散出去,由可注射态转化为水凝胶固态,再粘附在组织表面,因此可用于微创环境下的快速止血。
(3)本发明的水凝胶选用的分别带正电、负电的天然和/或合成高分子材料赋予了水凝胶优异的抗菌性。另外,采用的原料所能够被生物降解或吸收,减少残留问题。
(4)本发明的水凝胶在使用时因为可注射止血水凝胶的粘稠溶液和血液的盐浓度不同,实现了水凝胶在微创环境下的靶向止血。
(5)本发明利用醛基化A组分高分子材料、邻苯二酚化B组分高分子材料和一价无机盐溶液配置水凝胶,能够使得水凝胶对于不出血的健康组织不会产生盐浓度差,也不会产生粘附,因此对周围健康的组织无粘连的风险。
(6)本发明的制备方法将透明质酸进行部分醛基化,即把相邻的糖羟基氧化为醛基,得到带醛基的透明质酸(HA-CHO),后续醛基能够与组织中大量的氨基发生共价反应提高湿粘结强度;将季胺化壳聚糖接枝了部分邻苯二酚基团,修饰成带邻苯二酚的季胺化壳聚糖(QCS-DOPA),更大程度的提高水凝胶对生物组织(尤其肝脏、十二指肠和肾脏)的粘结强度,进一步提高了水凝胶的湿粘附性能。
附图说明
附图仅用于示出具体实施例的目的,而并不认为是对本发明的限制。
图1a为使用本发明的水凝胶在大鼠的体内肝脏止血实验中第0s时的止血状态图;
图1b为使用本发明的水凝胶在大鼠的体内肝脏止血实验中第5.43s时的止血状态图;
图1c为使用本发明的水凝胶在大鼠的体内肝脏止血实验中第9.51s时的止血状态图;
图1d为使用本发明的水凝胶在大鼠的体内肝脏止血实验中第12.45s时的止血状态图;
图2为三组大鼠的体内肝脏止血过程的失血量对比图;
图3为三组大鼠的体内肝脏止血过程的止血时间对比图。
具体实施方式
下面结合附图和具体实施例,对本发明进行详细描述。
本发明的一个具体实施例,公开了一种抗粘连的可注射止血水凝胶,按质量份数,包括醛基化A组分高分子材料50-100份、邻苯二酚化B组分高分子材料50-100份和一价无机盐溶液500-1000份;其中,醛基化A组分高分子材料中的A组分高分子材料带负电,邻苯二酚化B组分高分子材料中的B组分高分子材料带正电;醛基化A组分高分子材料中的A组分高分子材料为带有糖醛酸的多糖类衍生物;邻苯二酚化B组分高分子材料中的B组分高分子材料为壳聚糖、明胶、聚酰亚胺或聚丙烯酸中的任意一种或多种;将制备好的醛基化A组分高分子材料和邻苯二酚化B组分高分子材料的复合物溶于一价无机盐溶液后,得到可注射止血水凝胶。将可注射止血水凝胶注射至伤口出血处,在可注射止血水凝胶和血液之间的盐浓度差驱动下铺展至伤口并形成固态水凝胶,同时A组分高分子材料的醛基与组织上的氨基发生席夫碱反应,B组分高分子材料的邻苯二酚与组织构建共价和非共价反应,粘附在伤口表面,从而达到止血的目的。另外,带相反电的醛基化A组分高分子材料和邻苯二酚化B组分高分子材料与一价无机盐溶液相组合构成的可注射止血水凝胶能够使得水凝胶还能够防止周围健康的组织粘连。
可选地,一价无机盐溶液为氯化钠或氯化钾溶液。
可选地,A组分高分子材料中,带有糖醛酸的多糖类衍生物优选为透明质酸、果胶、瓜尔胶、海藻酸钠、硫酸皮肤素、硫酸类肝素或硫酸软骨素等。B组分高分子材料中,壳聚糖、明胶、聚酰亚胺或聚丙烯酸为带有氨基、羟基或羧基等具有反应活性位点的高分子材料。
将可注射止血水凝胶注射至模拟出血的血液环境(如:生理盐水)中,其中,模拟血液的生理盐水为:质量分数为0.9%,摩尔浓度为0.15mol/L,pH为6.8的氯化钠溶液,可注射水凝胶的粘稠溶液中一价无极盐溶液的小分子盐能够快速扩散,快速扩散时能够促进带负电的透明质酸和带正电的季胺化壳聚糖发生静电相互作用,增进物理交联,使得水凝胶能够快速完成溶胶-凝胶转变,同时,进一步修饰的醛基、邻苯二酚在凝胶状的载体上与组织发生共价相互作用,产生粘附,达到止血的目的,而对于健康的组织,因为没有伤口分泌血液,不会诱发可注射水凝胶的溶胶-凝胶转变,而修饰的醛基和邻苯二酚基团没有凝胶的载体,产生粘附弱,无法实现粘附,因此不会对健康的组织产生粘连。
本发明的另一个实施例,公开了一种抗粘连的可注射止血水凝胶的制备方法,用于制备上述抗粘连的可注射止血水凝胶,包括以下步骤:
制备醛基化A组分高分子材料:按照质量份数,获取带有负电的A组分高分子材料50-100份、高碘酸钠(即:NaIO4)10-30份、去离子水和无水乙醇10-20份;将A组分高分子材料溶于去离子水中获得质量浓度为1%-4%的A组分高分子材料溶液,将高碘酸钠溶于去离子水中获得质量浓度为2%-8%的NaIO4溶液;以600-1500rpm/min的速度搅拌A组分高分子材料溶液,边搅拌边向A组分高分子材料溶液中逐滴加入NaIO4溶液,并于室温和黑暗条件下反应12-24h;向A组分高分子材料溶液中加入无水乙醇,以600-1500rpm/min的速度搅拌2-4h,获得A组分高分子材料反应溶液;将A组分高分子材料反应溶液倒入去离子水1000-5000份中透析4-8天,冷冻干燥至无质量变化后,获得醛基化A组分高分子材料。其中按照质量份数计算,醛基化的部分占A组分高分子材料的30%-70%,优选45%-60%;优选地,获取带有负电的A组分高分子材料50份、高碘酸钠10份、去离子水和无水乙醇10份,A组分高分子材料溶液的质量浓度为2%,NaIO4溶液的质量浓度为4%,搅拌速度为600rpm/min,反应时间为24h,透析时间为4天。
制备邻苯二酚化B组分高分子材料:按照质量份数,获取带有正电的B组分高分子材料50-100份、磷酸缓冲液5000-10000份、3,4-二羟基苯乙酸2-4份、1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐2-4份、去离子水和无水乙醇100-200份;将带有正电的B组分高分子溶于磷酸缓冲液中获得质量浓度为1%-4%的B组分高分子溶液,将3,4-二羟基苯乙酸溶于去离子水中获得质量浓度为2%-4%的3,4-二羟基苯乙酸溶液,将1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐)溶于质量比1: 1的去离子水和无水乙醇中获得质量浓度为2%-4%的1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐)溶液。将3,4-二羟基苯乙酸溶液和1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐溶液逐滴加入B组分高分子材料溶液获得混合液,并于室温下反应12-24h,并且每隔15-30min检查混合液pH值是否在5.0-5.5之间,如果pH值在5.0-5.5之间则继续反应,如果pH值不在5.0-5.5之间则滴加盐酸调整pH值,最终获得B组分高分子材料反应溶液;将B组分高分子材料反应溶液倒入去离子水1000-5000份中透析4-8天,冷冻干燥至无质量变化,获得了邻苯二酚化B组分高分子材料。其中按照质量份数计算,邻苯二酚化的部分占B组分高分子材料的5%-30%,优选10%-15%;优选地,获取带有正电的B组分高分子材料50份、磷酸缓冲液5000份、3,4-二羟基苯乙酸2份、1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐2份、去离子水和无水乙醇100份,B组分高分子溶液的质量浓度为1%,3,4-二羟基苯乙酸溶液的质量浓度为2%,1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐)溶液的质量浓度为2%,磷酸缓冲液的pH为5.0,反应时间为12h,透析时间为4天,每隔15min检查混合液pH值。
将醛基化A组分高分子材料50-100份溶于去离子水1000-2000份中获得质量浓度为2.5%-5%的醛基化A组分高分子材料溶液;将邻苯二酚化B组分高分子材料50-100份溶于去离子水2500-5000份中获得质量浓度为1%-2%的邻苯二酚化B组分高分子材料溶液。
将醛基化A组分高分子材料溶液和邻苯二酚化B组分高分子材料溶液按照体积比1:1-2:1的比例混合,以600-1500rpm速率的搅拌10-30min得到复合物;对复合物进行离心处理,离心速率为5000-7000rpm/min,离心时间3-5min;将离心后的复合物冷冻干燥至无明显质量变化后抽取50-100份溶于摩尔浓度1-6mol/L氯化钠溶液500-1000份中,得到可注射止血水凝胶。其中,离心速率优选为7000rpm/min,离心时间优选为5min。优选地,氯化钠溶的摩尔浓度为1mol/L。
将可注射止血水凝胶注射至出血创口处,无需任何外界操作,可注射止血水凝胶自发地铺展和粘附在组织表面,并形成固态水凝胶来达到止血的目的,同时对周围健康的组织不产生粘连的风险。优选地,出血创口长2.5 cm,深2 cm时,可注射止血水凝胶的用量为3-5 mL。
本发明的另一个实施例,将前述可注射止血水凝胶应用在制备医疗材料中。
实施例1
制备醛基化-透明质酸(HA-CHO)聚合物:按照质量份数,称取50g带有负电的透明质酸(即:HA,分子量为10万-15万)、10g高碘酸钠、去离子水和10mL无水乙醇;将透明质酸溶于去离子水中获得质量浓度为2%的透明质酸溶液,将高碘酸钠溶于去离子水中获得质量浓度为4%的NaIO4溶液;以600rpm/min的速度进行搅拌透明质酸溶液,边搅拌边向透明质酸溶液中逐滴加入NaIO4溶液,并于室温和黑暗条件下反应24h;24h反应后加入无水乙醇以600rpm/min的速度搅拌2h,获得透明质酸反应溶液;停止反应后将反应溶液倒入5L去离子水中透析4天,冷冻干燥至无质量变化后获得醛基化-透明质酸(HA-CHO)聚合物;按照质量份数,透明质酸的醛基化程度占透明质酸的50%。
制备邻苯二酚化-季胺化壳聚糖(QCS-DOPA)聚合物:称取带有正电的50 g季胺化壳聚糖、5000 mL的pH为5.0的磷酸缓冲液、2 g的3,4-二羟基苯乙酸和2 g的1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐、去离子水和无水乙醇100mL;将带有正电的季胺化壳聚糖溶于磷酸缓冲液中获得质量浓度为1%的季胺化壳聚糖溶液,将3,4-二羟基苯乙酸溶于去离子水中获得质量浓度为为2%的3,4-二羟基苯乙酸溶液,将1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐)溶于质量比1:1的去离子水和无水乙醇中获得质量浓度为2%的1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐)溶液。将3,4-二羟基苯乙酸溶液和1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐)溶液逐滴加入季胺化壳聚糖溶液获得混合液,于室温下反应12h,每隔15min检查混合液pH值是否在5.0-5.5之间,如果pH值在5.0-5.5之间则继续反应,如果pH值不在5.0-5.5之间则滴加盐酸调整pH值,最终获得季胺化壳聚糖反应溶液;将季胺化壳聚糖反应溶液倒入去离子水5L中透析4天,冷冻干燥至无质量变化后获得邻苯二酚化-壳聚糖(QCS-DOPA)聚合物;按照质量份数,邻苯二酚化程度占季胺化壳聚糖的10%。
将50g醛基化-透明质酸溶于去离子水1000g中获得质量浓度为5%的醛基化透明质酸溶液(即:HA-CHO溶液);将50g邻苯二酚化-壳聚糖聚合物溶于去离子水2500g中获得质量浓度为2%的邻苯二酚化壳聚糖溶液(即:QCS-DOPA溶液)。
将醛基化透明质酸溶液和邻苯二酚化-壳聚糖按照体积比1:1混合,以1000rpm/min的速度搅拌10min得到复合物;对复合物进行离心处理,离心速率为7000rpm/min,离心时间为3-5min;将离心后的复合物冷冻干燥4天至无明显质量变化后,称取50g溶于500mL摩尔浓度为1mol/L的氯化钠溶液中获得可注射止血水凝胶。
利用上述实施例1的水凝胶,将雄性体重为250g的Sprague-Dawley大鼠随机分为三组,每一组都进行相同的如下操作:首先腹膜内以20mg/kg的量注射戊巴比妥钠进行麻醉;随后进行腹部切口以暴露肝脏,并使用无菌纱布将周围的浆液吸干;在肝脏表面创造约长2.5cm,深2cm的切口;0s时切口有大量血液流出,此时,立即将5mL实施例1的水凝胶注入第一组大鼠的切口部位,5-10s后水凝胶铺展并覆盖了全部的创伤切口,经过凝胶化和粘附后组织后,约12s-16s后可观察到出血较少直至止血,同时不会对周围健康的组织产生粘连。图1a-图1d展示了使用本发明的水凝胶的大鼠的体内肝脏在0s、5.43s、9.51s和12.45s时的止血状态,其中,图1a,第0s时,注射可注射止血水凝胶自发凝胶化;图1b,第5.43s时,可注射止血水凝胶自发铺展至伤口处;图1c,第9.51s时,可注射止血水凝胶自发凝胶化;图1d,第12.45s时,伤口停止出血。
对于第二组大鼠,0s时切口有大量血液流出,此时,立即将5mL纤维蛋白胶注入第二组大鼠的切口部位。对于第三组大鼠,不使用任何措施。
如图2-图3所示,为利用上述实施例1的可注射止血水凝胶和纤维蛋白胶开展大鼠肝脏止血实验的失血量和止血时间以及不使用任何措施的空白组的失血量和止血时间。
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到的变化或替换,都应涵盖在本发明的保护范围之内。

Claims (6)

1.一种抗粘连的可注射止血水凝胶,其特征在于,包括醛基化A组分高分子材料、邻苯二酚化B组分高分子材料和一价无机盐溶液;
其中,醛基化A组分高分子材料中的A组分高分子材料带负电,邻苯二酚化B组分高分子材料中的B组分高分子材料带正电;
醛基化A组分高分子材料中的A组分高分子材料为带有糖醛酸的多糖类衍生物;邻苯二酚化B组分高分子材料中的B组分高分子材料为壳聚糖、明胶、聚酰亚胺或聚丙烯酸中的任意一种或多种。
2.根据权利要求1所述的一种抗粘连的可注射止血水凝胶,其特征在于,按质量份数,醛基化A组分高分子材料50-100份、邻苯二酚化B组分高分子材料50-100份和一价无机盐溶液500-1000份。
3.根据权利要求1或2所述的一种抗粘连的可注射止血水凝胶,其特征在于,一价无机盐溶液为氯化钠或氯化钾溶液。
4.根据权利要求1或2所述的一种抗粘连的可注射止血水凝胶,其特征在于,多糖类衍生物为透明质酸、果胶、海藻酸钠、硫酸皮肤素、硫酸类肝素或硫酸软骨素中的任意一种或多种。
5.一种抗粘连的可注射止血水凝胶的制备方法,用于制备权利要求1-4任一项所述的水凝胶,包括以下步骤:
制备醛基化A组分高分子材料:获取A组分高分子材料、高碘酸钠溶液、水和乙醇;混合A组分高分子材料和高碘酸钠溶液获得A组分高分子材料溶液;向A组分高分子材料溶液中加入乙醇获得A组分高分子材料反应溶液;将A组分高分子材料反应溶液倒入水中透析,然后冷冻干燥至无质量变化后,获得醛基化A组分高分子材料;
制备邻苯二酚化B组分高分子材料:获取B组分高分子材料、磷酸缓冲液、3,4-二羟基苯乙酸、1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐、水和乙醇;将B组分高分子材料溶于磷酸缓冲液中获得B组分高分子材料溶液;将3,4-二羟基苯乙酸溶于水中获得3,4-二羟基苯乙酸溶液;将1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐溶于水和乙醇中获得1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐溶液;混合3,4-二羟基苯乙酸溶液、1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐溶液和B组分高分子材料溶液获得B组分高分子材料反应溶液;将B组分高分子材料反应溶液倒入水中透析,然后冷冻干燥至无质量变化,获得邻苯二酚化B组分高分子材料;
将醛基化A组分高分子材料溶于水中获得醛基化A组分高分子材料溶液;将邻苯二酚化B组分高分子材料溶于水中获得邻苯二酚化B组分高分子材料溶液;
将醛基化A组分高分子材料溶液和邻苯二酚化B组分高分子材料溶液混合得到复合物;对复合物进行离心处理,将离心后的复合物冷冻干燥后溶于一价无机盐溶液中,得到抗粘连的可注射止血水凝胶。
6.权利要求1-4任一项所述的抗粘连的可注射止血水凝胶在制备医疗材料中的应用。
CN202211112444.5A 2022-09-14 2022-09-14 一种抗粘连的可注射止血水凝胶、制备方法及应用 Active CN115177780B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211112444.5A CN115177780B (zh) 2022-09-14 2022-09-14 一种抗粘连的可注射止血水凝胶、制备方法及应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211112444.5A CN115177780B (zh) 2022-09-14 2022-09-14 一种抗粘连的可注射止血水凝胶、制备方法及应用

Publications (2)

Publication Number Publication Date
CN115177780A true CN115177780A (zh) 2022-10-14
CN115177780B CN115177780B (zh) 2022-11-29

Family

ID=83524192

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211112444.5A Active CN115177780B (zh) 2022-09-14 2022-09-14 一种抗粘连的可注射止血水凝胶、制备方法及应用

Country Status (1)

Country Link
CN (1) CN115177780B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116426168A (zh) * 2023-03-13 2023-07-14 北京航空航天大学 一种基于水凝胶的超浸润性对多种基底进行涂层修饰的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448474A (zh) * 2006-04-12 2009-06-03 麻省理工学院 抑制粘连的组合物和方法
WO2013123946A1 (en) * 2012-02-20 2013-08-29 Aarhus Universitet Multi-responsive self-healing polymer and gel compositions
EP2974744A1 (en) * 2014-07-16 2016-01-20 Stichting Katholieke Universiteit Strain-promoted oxidation controlled cycloaddition with high reaction rate
CN113209363A (zh) * 2021-04-30 2021-08-06 暨南大学 一种粘附止血可注射壳聚糖凝胶及其制备方法与应用
CN114712550A (zh) * 2022-04-20 2022-07-08 华中科技大学 一种可注射快速止血的水凝胶粘合剂及制备方法、应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448474A (zh) * 2006-04-12 2009-06-03 麻省理工学院 抑制粘连的组合物和方法
WO2013123946A1 (en) * 2012-02-20 2013-08-29 Aarhus Universitet Multi-responsive self-healing polymer and gel compositions
EP2974744A1 (en) * 2014-07-16 2016-01-20 Stichting Katholieke Universiteit Strain-promoted oxidation controlled cycloaddition with high reaction rate
CN113209363A (zh) * 2021-04-30 2021-08-06 暨南大学 一种粘附止血可注射壳聚糖凝胶及其制备方法与应用
CN114712550A (zh) * 2022-04-20 2022-07-08 华中科技大学 一种可注射快速止血的水凝胶粘合剂及制备方法、应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHENGYUAN SUN: "Bio-adhesive catechol-modified chitosan wound healing hydrogel dressings through glow discharge plasma technique", 《CHEMICAL ENGINEERING JOURNAL》 *
HONGBIN LI: "Antibacterial, hemostasis, adhesive, self-healing polysaccharides-based composite hydrogel wound dressing for the prevention and treatment of postoperative adhesion", 《MATERIALS SCIENCE & ENGINEERING C》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116426168A (zh) * 2023-03-13 2023-07-14 北京航空航天大学 一种基于水凝胶的超浸润性对多种基底进行涂层修饰的制备方法
CN116426168B (zh) * 2023-03-13 2024-05-28 北京航空航天大学 一种基于水凝胶的超浸润性对多种基底进行涂层修饰的制备方法

Also Published As

Publication number Publication date
CN115177780B (zh) 2022-11-29

Similar Documents

Publication Publication Date Title
US10159742B2 (en) Hydrogel compositions
CN110522948B (zh) 可注射水凝胶及其制备方法和应用
EP1794192B1 (en) Photoreactive polysaccharide, photocrosslinked polysaccharide products, the method of making them and medical materials made therefrom
US20100035838A1 (en) Cross-linked polysaccharide gels
CN106589424A (zh) 一种注射用交联透明质酸凝胶及其制备方法
CN106075553A (zh) 一种生物医用粘合剂及其制备方法
Fang et al. Polysaccharides based rapid self-crosslinking and wet tissue adhesive hemostatic powders for effective hemostasis
JP2008133474A (ja) 架橋多糖類組成物
CN115177780B (zh) 一种抗粘连的可注射止血水凝胶、制备方法及应用
CN110003506A (zh) 一种高强度可注射胶束交联多糖水凝胶的制备方法
Zhao et al. Synthesis and characterization of a novel double crosslinked hyaluronan hydrogel
CN104761734B (zh) 一种氨基酸交联透明质酸钠凝胶的制备方法
CN115554462A (zh) 一种抗溶胀的可注射水凝胶粘接剂及其制备方法
CN112843325A (zh) 一种医用水凝胶粘合剂及其制备方法和用途
KR20130093769A (ko) 카테콜 기를 가지는 감마 폴리글루탐산, 이의 제조 방법 및 이를 포함하는 조직 접착제
US20100260845A1 (en) Biocompatible and Biodegradable Biopolymer Matrix
CN111484611A (zh) 含有硫酯与醛基的聚乙二醇聚合物及其制备方法、包含其的化学交联水凝胶与应用
CN113842494B (zh) 一种促进组织再生的可注射止血晶胶及其制备方法和应用
CN105770983B (zh) 一种透明质酸生物粘合剂的制备方法
CN111053946B (zh) 一种基于多糖和超支化多肽的双组分组织粘合剂及其制备方法
CN110229357A (zh) 一种新的交联透明质酸凝胶的制备方法
CN114470306B (zh) 基于壳聚糖的生物组织粘合剂及其制备方法与应用
CN113388049A (zh) 一种大分子衍生物及其制备方法和在生物组织粘合剂中的应用
de Azevedo Aldehyde-functionalized chitosan and cellulose: chitosan composites: application as drug carriers and vascular bypass grafts
CN112220963B (zh) 一种非溶胀uv交联壳聚糖可注射水凝胶及其合成方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant